Sida cordifolia roots
PreclinicalSmall molecule
Sida cordifolia roots is one of 11 small molecule programs targeting Polyneuropathy. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Polyneuropathy
#DrugCompanyPhaseTrials
1Keppra
UCBApproved
Tofranil
SanofiApproved
Lexapro
AbbVieApproved
Vyndaqel
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Dilantin
VViatris Specialty LLC
Approved
Wainua (autoinjector)
AstraZenecaPhase 3
Brukinsa
BBeOne Medicines
Phase 2
Onpattro
Alnylam PharmaceuticalsPreclinical
HB-Admscs
HHope Biosciences Research Foundation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sida cordifolia roots. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details